Plain-English translation of NCT06810726 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called Tropocells® Autologous Platelet-rich Fibrin (PRF), which is a gel made from your own blood that may help heal chronic diabetic foot ulcers. Researchers will apply this treatment directly to your wound during regular clinic visits over 12 weeks to see if it helps your ulcer close completely. The goal is to understand whether this medication is safe and effective for people with diabetes who have difficult-to-heal foot wounds.
Many people with diabetes develop chronic foot ulcers that don't heal well with standard wound care alone, leading to serious complications. This trial exists to test whether using a treatment made from the patient's own blood platelets can give wounds a better chance of healing.
You likely qualify if…
You likely don't qualify if…
First, you'll have a 2-week screening period where you visit the clinic weekly for standard wound care—cleaning, measurements, photos, and wearing an off-loading boot. If your wound doesn't improve more than 20% during this time, you'll move into the active treatment phase, where you'll receive the new gel treatment applied directly to your wound during weekly clinic visits for 12 weeks, along with continued standard care. Once your wound is completely closed, you'll have follow-up visits at 1 month and 3 months to make sure it stays healed.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States